CardioMEMS Wins 2012 Intel Innovation Award
ATLANTA — December 11, 2012 — CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced today that it has been honored as the 2012 recipient of the Intel Innovation Award. Founder and CEO Jay Yadav, M.D., was presented with the award on December 4th during the annual Health IT Leadership Summit held at the historic Fox Theatre in Atlanta, GA.
"CardioMEMS unites two areas where Georgia has strengths – health IT and medical devices," said David B. Hartnett, Vice President, Bioscience & Health IT Development, Metro Atlanta Chamber. “This truly innovative company integrates these two disciplines to create advanced technology that holds huge promise for heart failure patients. We are proud that they are part of the Atlanta healthcare community, and look forward to watching their continued success."
"It was a challenging decision, given the high level of competition for this award," said Dan Rivera, Area Director, Intel Americas. "Ultimately, CardioMEMS was chosen as the winner based on its ground-breaking technology and novel use of health IT to reduce the burden on our healthcare system."
"We are honored to be recognized by Intel, a leader in innovative solutions," said Dr. Yadav. "This is a testament to the extraordinary efforts of the CardioMEMS team to generate precise, timely, actionable information to address the tremendous burden heart failure places on the U.S. healthcare system and on patients suffering from this debilitating disease. We are fortunate to have the considerable support of the Technology Association of Georgia, the Metro Atlanta Chamber and the Georgia Department of Economic Development as we continue to bring CardioMEMS’ revolutionary technology to market."
About CardioMEMS, Inc.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
# # #
Investor and Media Contact:
CardioMEMS and the CardioMEMS Logo are registered trademarks of CardioMEMS, Inc.
|©2012 CardioMEMS, Inc.|